Key facts
- Akeso is expanding manufacturing of its lung cancer drug, ivonescimab.
- The drug showed positive clinical results in trials.
Akeso drug shows promise in lung cancer trials
IN SHORT
Akeso is expanding manufacturing of its lung cancer drug, ivonescimes, following positive clinical trial results. The drug showed a reduced risk of death in trials and analysts suggest it could become a backbone therapy in the global non-small cell lung cancer market.
Key Numbers
34%reduced risk of death in prior trial
$20 billionglobal non-small cell lung cancer market size
Who's Involved
Akeso
Chinese biotech firm expanding manufacturing of lung cancer drug
ivonescimab
Akeso's experimental lung cancer drug
Summit Therapeutics
Collaborator on the experimental lung cancer drug
American Society of Clinical Oncology
Hosted annual meeting where Akeso presented results
↳ Why This Matters
Akeso's experimental lung cancer drug, ivonescimab, has shown promising results in clinical trials, including a reduced risk of death. The company is investing to expand manufacturing, anticipating demand in China and the US, and analysts believe it could become a significant therapy in the substantial global non-small cell lung cancer market.